Future treatment of Parkinson's disease.
New methods of drug delivery and slowing down the progression of Parkinson's disease (PD) are the major goals of research. More steady drug levels in the blood are possible by means of controlled-release preparations of levodopa and long-acting dopamine agonists, as well as transcutaneous duodenal tubes and pumps for controlled subcutaneous infusion. Patches containing dopamine agonists absorbed through the skin may be developed. The role of D1 agonists as compared with D2 agonists remains to be elucidated. Agonists on autoreceptors of dopaminergic neurons may potentially reduce excessive stimulation of the intact neurons and this may slow down the rate of neuronal death in PD. Monoamine oxidase-B inhibitors may have a potentially protective action on neurons. Investigations are being carried out to evaluate this claim. Catechol-o-methyl-transferase inhibitors may be helpful in theory. There is also recent interest in inhibitors of excitatory amino acids, which may contribute to neuronal loss in PD.
Tsui
J K
JK
Department of Medicine, University of British Columbia, Vancouver, Canada.
D000818:Animals; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D005544:Forecasting; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy*
D000978:Antiparkinson Agents